Seeking Alpha

Today's drop in shares of Discovery Labs (DSCO -4.3%) reflects nervousness over next week's...

Today's drop in shares of Discovery Labs (DSCO -4.3%) reflects nervousness over next week's expected FDA decision on Surfaxin, DSCO's drug for prevention of respiratory distress syndrome in premature infants. FDA Tracker is pessimistic about approval, saying DSCO won't be able to demonstrate bioequivalence since it changed the formulation.
Comments (1)
  • DougRk
    , contributor
    Comments (1619) | Send Message
     
    DSCO has a very high hurdle after altering their compound slightly for manufacture. They have to prove bio-equivalence of the compounds. If they're denied here, and sentiment becomes that they have to re-investigate to any serious extent, the stock will be off more than the usual 50% IMO.

     

    I couldn't jump in on this one, just too much risk.

     

    http://bit.ly/xEk8mG
    6 Mar 2012, 12:45 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs